Trials
Search / Trial NCT05659576

Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Dec 13, 2022

Trial Information

Current as of February 05, 2025

Recruiting

Keywords

Gastrointestinal Sucralfate Radiation Therapy Thoracic Cancer 22 307

ClinConnect Summary

This clinical trial is looking at ways to prevent and reduce the side effects of radiation therapy that can affect the esophagus, a condition known as radiation esophagitis. Researchers want to find out what symptoms patients experience during treatment and if there is any noticeable weight loss among participants. The goal is to improve comfort and health for those receiving thoracic radiation therapy.

To be eligible for the study, participants need to be 18 years or older and undergoing thoracic radiation with specific dosage criteria related to the esophagus. For instance, they must have a certain level of radiation exposure to the esophagus. However, individuals who cannot take a medication called Sucralfate, have a feeding tube, are taking opioid pain medications before starting radiation, or have a history of opioid use disorder are not eligible. If you participate, you can expect to share your experiences and symptoms during treatment, which will help researchers learn more about managing these side effects in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients being treated with thoracic irradiation with high-risk esophageal dose as determined below:
  • Esophageal dose:
  • V50 ≥ 15% (25-35 once daily fractions) or 40 twice-daily \[BID\] fractions)
  • V40 ≥ 15% (15-24 once daily fractions or 30 twice-daily \[BID\] fractions)
  • V30 ≥ 15% (10-14 once daily fractions)
  • Age 18 years of age or older.
  • Exclusion Criteria:
  • Known inability to take Sucralfate (tablet and/or suspension form), per physician discretion
  • PEG tube
  • Actively taking any opioid pain medications prior to radiation therapy
  • History of an opioid use disorder

Trial Officials

Jacob Shin, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Harrison, New York, United States

Middletown, New Jersey, United States

Montvale, New Jersey, United States

Uniondale, New York, United States

Commack, New York, United States

Basking Ridge, New Jersey, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials